Publication | Closed Access

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Moderately-to-severely Active CrohnImmunologyGastroenterologyClinical GastroenterologyUlcerative ColitisMedicineTreat-through StudyPhase 3